Targeting the GCK pathway: a novel and selective therapeutic strategy against RAS-mutated multiple myeloma
Shirong Li(Luye Pharma (China)), Suzanne Lentzsch(Columbia University Irving Medical Center)
Cited by 18
Related Papers
Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma
|Blood|2001|905
International myeloma working group consensus recommendations on imaging in monoclonal plasma cell disorders
|The Lancet Oncology|2019|493
Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group
|The Lancet Oncology|2021|266
A paper-supported aptasensor based on upconversion luminescence resonance energy transfer for the accessible determination of exosomes
|Biosensors and Bioelectronics|2017|151
Multiple myeloma–derived MMP-13 mediates osteoclast fusogenesis and osteolytic disease
|Journal of Clinical Investigation|2016|73